NCT00370942View on ClinicalTrials.gov

GW823093C For The Treatment Of Type 2 Diabetes Mellitus

PHASE2TerminatedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

April 1, 2006

Primary Completion Date

November 1, 2006

Study Completion Date

November 25, 2006

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GW823093C A

A=45 mg

DRUG

GW823093C B

B=30 mg

DRUG

GW823093C C

C=25 mg

Trial Locations (5)

051-0005

GSK Investigational Site, Hokkaido

985-0852

GSK Investigational Site, Miyagi

130-0004

GSK Investigational Site, Tokyo

160-0017

GSK Investigational Site, Tokyo

Unknown

GSK Investigational Site

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY